Bulløse hudsygdomme
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 821 KB, PDF-dokument
This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.
Bidragets oversatte titel | Bullous skin diseases |
---|---|
Originalsprog | Dansk |
Artikelnummer | V06220400 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 184 |
Udgave nummer | 41 |
Antal sider | 8 |
ISSN | 0041-5782 |
Status | Udgivet - 2022 |
- Autoimmune Diseases, Azathioprine/adverse effects, Glucocorticoids, Humans, Methotrexate/adverse effects, Pemphigus/chemically induced, Rituximab/therapeutic use, Skin Diseases, Vesiculobullous/chemically induced
Forskningsområder
Links
- https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-09/v06220400_web.pdf
Forlagets udgivne version
ID: 326028285